Alpha Teknova, Inc.

As of August 11, 2021, Alpha Teknova, Inc. is considered overvalued and risky due to high valuation metrics and poor financial performance, with a year-to-date return of -44.43%, significantly underperforming the S&P 500.

As of August 11, 2021, Alpha Teknova, Inc. is considered overvalued with a risky valuation grade, reflected by poor financial metrics and a year-to-date stock performance decline of 36.77%, significantly underperforming compared to its peers and the S&P 500.

As of May 27, 2025, the market trend has shifted to mildly bearish, primarily due to bearish signals from the weekly MACD and Bollinger Bands, despite some mixed bullish indicators on the monthly timeframe.

Alpha Teknova, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $10 million and a net loss of $5 million as of March 2025. It has a market cap of $288.05 million, with key metrics indicating no earnings and a negative return on equity.

As of Jun 18, Alpha Teknova, Inc. has a market capitalization of 288.05 million and reported net sales of 38.25 million with a net profit of -23.29 million over the latest four quarters.